Supercharge Your Innovation With Domain-Expert AI Agents!

Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis b virus infection

A cytotoxic, restrictive technology for use in medicine and immunology that addresses high costs, toxic side effects of antiviral therapy, and inability to eradicate infection with antiviral drugs

Active Publication Date: 2017-04-19
ISA PHARM BV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the inability of antiviral drugs to eradicate the infection and thus the need for long-term (if not life-long) antiviral therapy (with disadvantages such as toxic side effects and high costs), new therapeutic approaches are urgently needed (Grimm et al., 2013)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis b virus infection
  • Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis b virus infection
  • Synthetic long peptides (SLP) for therapeutic vaccination against hepatitis b virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0165] introduction

[0166] In the present invention, the present inventors developed an optimal vaccine composition for inducing T cells consisting of synthetic long peptides to treat patients with chronic HBV infection. Thirty-seven long peptides (Table 3; sequences ranging from 30 to 39 amino acids) were selected that contained regions of HBV polymerase, core protein, surface antigen and protein X with the highest putative ability to induce T cell immunity. For this purpose, an algorithm (which predicts HLA class I and II binding and all HLA class I binding short peptides (with the length of a CTL epitope, 8-12 amino acids) contained in HBV proteins was first performed by the proteasome C-terminal generation) to identify putative HLA class I-restricted cytotoxic T-cell (CTL) epitopes and putative HLA class II-restricted helper T-cell epitopes in these proteins. Numerical values ​​were assigned to all putative CTL epitopes and helper T cell epitopes reflecting their immuno...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the fields of medicine and immunology. In particular, it relates to novel peptides that may be used in the treatment and / or prevention of a Hepatitis B viral infection and / or an Hepatitis B related disease or condition.

Description

technical field [0001] The present invention relates to the fields of medicine and immunology. In particular, the present invention relates to novel peptides useful for the treatment and / or prevention of hepatitis B virus infection and / or hepatitis B related diseases or conditions. Background technique [0002] Chronic infection with hepatitis B virus (HBV) is a major global health problem. HBV is a prototypical member of the Hepadnaviridae family with a strong preference for infecting hepatocytes (Ganem et al, 2004). [0003] Although an effective preventive vaccine conferring protection against hepatitis B has been available since 30 years ago, an estimated 2 billion people have been infected with HBV and more than 240 million people currently suffer from chronic (long-term) hepatitis B infection in Western Europe geographically dominant in regions outside of North America and North America (World Health Organization, July 2013). [0004] Human-to-human transmission of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/02A61K39/29A61P31/20
CPCA61K39/12C07K14/005A61K2039/572A61K38/00C12N2730/10134C12N2730/10122A61P1/16A61P31/20A61P37/04C07K14/70539A61K38/1774A61K39/292A61K2039/53
Inventor W·J·T·A·克雷伯J·H·凯斯勒C·J·M·梅立夫K·M·C·科瓦朋伯格
Owner ISA PHARM BV
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com